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Abstract 
There are many claims surrounding the health benefits of consuming green tea, some of which 
involve its use in the treatment of medical conditions as wide ranging as cancer, diabetes, and 
neurodegenerative disorders. The desire for the use of non-toxic and natural drugs to treat 
various diseases makes any health-benefitting claims about green tea and its components 
important to investigate for their potential public health benefits. I conducted a critical review of 
the research literature on green tea and its effects on human health and synthesized the results. 
There is convincing epidemiological evidence pointing to the health benefits derived from 
consumption of green tea, but National Institutes of Health (NIH)-funded clinical trials are few 
in number and have produced only modest results. The main biologically active compound in 
green tea, epigallocatechin gallate (EGCG), does not demonstrate specific binding to biological 
molecules and varies greatly in its concentration in green tea. EGCG also has a weak, but 
notable, relationship between dose and maximum plasma concentration in humans; however, 
most concentrations of EGCG used in laboratory studies are far beyond the physiologically 
achievable levels. Additionally, there is evidence that high doses of EGCG may lead to liver 
damage. Finally, green tea polyphenols are implicated in a vast number of interactions, but these 
are not well understood and suggest the possibility of pan-assay interference. Without clear 
mechanistic evidence or reliable dosing strategies, it is unlikely that green tea will be suitable for 
pharmaceutical uses in the treatment of human disease. 
Introduction 
Green tea is claimed by the news media and scientists alike to be a source of health benefits for 
many conditions in humans. However, with the supposed health benefits of green tea ranging 
from ultraviolet light protection to memory improvement to weight management, it can be 
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difficult to separate fact from fiction. Scientists have a renewed interest in utilizing natural 
remedies in modern medicine, and nutrition researchers have begun to focus on determining the 
role of bioactive compounds in the pathology of diseases (Kris-Etherton and Keen 2002). In 
recent years, the research focus has shifted towards the role of bioactive compounds in the 
prevention and treatment of diseases (Khan and Mukhtar 2013; Kris-Etherton and Keen 2002; 
McKay and Blumberg 2002). For many centuries, tea has been considered one of the most 
beneficial sources of bioactive compounds (Narotzki et al. 2011; Serafini et al. 2011). In 1211, 
for example, the Japanese Zen priest Yeisai published the book Kitcha-Yojoki, translated as “Tea 
and Health Promotion”, describing the pharmaceutical applications of green tea, Camellia 
sinensis Theaceae (Suzuki et al. 2012). Much has changed since 1211, but the public’s 
fascination with tea and its health benefits have remained. Because tea is the most consumed 
beverage in the world aside from water, even small beneficial health effects in humans could 
result in significant effects in global public health (Kuriyama et al. 2006; Rimm and Stampfer 
2004). 
 Numerous epidemiological studies provide support for green tea's role in preventing and 
treating many disorders (Hertog et al. 1995; Iso et al. 2006; Kris-Etherton and Keen 2002; 
Kuriyama et al. 2006; Mozaffari-Khosravi et al 2013; Odegaard et al. 2008; Sesso et al. 1999; 
Yang et al 2004). These epidemiological studies suggest a relationship between drinking green 
tea and positive health outcomes; however, epidemiological studies are not capable of 
determining if green tea is directly causing these outcomes. While many epidemiological studies 
provide valuable insight into real-world effects of green tea consumption on human health, many 
confounding variables exist (Riemersma et al. 2001). These variables include gender, weight, 
diet, activity, smoking, coffee consumption, genetics, etc. Though epidemiologists work to 
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control many of these confounding variables, it is not possible to completely control for all of 
them. A more direct way to evaluate green tea’s health benefits is to determine: 1) the specific 
components in green tea producing the effects, i.e., bioactive molecules; 2) how these bioactive 
molecules produce the effects, i.e., their mechanism of action; and 3) the availability of these 
molecules to cells in the body, i.e., their bioavailability. These characteristics can only be 
evaluated in clinical and laboratory studies. 
There are numerous bioactive molecules in green tea, but most attention has focused on 
polyphenols. Green tea is rich in polyphenols, which are antioxidant compounds capable of 
neutralizing highly reactive molecules called free radicals (Kim et al. 2014; Quideau et al. 2011). 
Although best known for their antioxidant properties, polyphenols may have antiviral, 
antibacterial, and gene regulation properties (Kim et al. 2014; Kozłowska and Szostak-Węgierek 
2014). The most studied polyphenol in green tea is epigallocatechin gallate (EGCG) (Williamson 
and Manach 2005). A recent search for “green tea” in the major biomedical literature database 
PubMed produced over 5,000 articles, and a search for “EGCG” yielded more than 4,000 
articles. A quick scan of the review articles published in 2014 alone revealed studies of green tea 
within the context of various cancers, infectious diseases, inflammation, oral health, cognitive 
mood and function, neurodegenerative diseases, and obesity. 
The observation of so many different biological effects purportedly arising from the 
ingestion of green tea raises concerns about the specificity of EGCG (Table 1). Recently, a new 
classification of chemicals deemed “pan-assay interfering” compounds, or PAINS, has cast 
doubt upon the usefulness of compounds such as EGCG as potential medical therapies (Baell and 
Walters 2014). Alternative names for PAINS include “frequent-hitters” and “promiscuous 
compounds”, as they often appear in a variety of unrelated pathways and systems (Bajorath 
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2014). Effective drugs are characterized by their ability to bind to a specific site on a protein, 
which thereby induces activation or inhibition of that particular protein (or pathway). 
Researchers measure the ability of drugs to bind proteins using various assays, but it has been 
suggested that PAINS are capable of "tricking" these assays into giving false-positive results 
(Baell and Walters 2014). PAINS may bind to a protein, but they do not bind in a specific 
location required for drug-like action, and therefore the binding signal may be an artifact and not 
an indication of specific biological activity (Baell and Walters 2014). EGCG has been flagged as 
a potential PAIN compound due to its apparent omnipresence in biological systems (Baell and 
Walters 2014). Some researchers have suggested that plant phytochemicals such as EGCG may 
act promiscuously in humans by altering membrane protein function and thus merely appear to 
be pervasively active (Ingólfsson et al. 2014). The pharmaceutical industry has understood for 
some time the importance of classifying these “bad actors”; however, researchers continue to 
publish papers ascribing the potential pharmaceutical applications of compounds that do not 
demonstrate specific biological activity (Baell 2010). Is it possible for one beverage to be a 
therapy for everything from prostate cancer to sunburn? Or, is it more likely that green tea’s 
apparent universal application is because it is a PAIN? 
In some cases, researchers propose cellular and molecular mechanisms by which green 
tea may produce a health benefit. EGCG’s classification as an antioxidant, however, only 
heightens concerns of non-specific interactions not suitable for pharmaceutical drug 
classification. Antioxidants act to neutralize the harmful effects of reactive oxygen species 
(ROS), such as peroxides, and reactive nitrogen species (NOS), such as peroxynitrate (Anissi et 
al. 2013). ROS and NOS contain extra electrons that attack other molecules, which can result in 
damage to proteins, DNA, etc. (Sullivan and Chandel 2014). Antioxidants, such as EGCG and 
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other green tea components, neutralize ROS and NOS, and thus act to prevent damage by these 
molecules (Sullivan and Chandel 2014). Pharmaceutical drugs are categorized in part by their 
specific binding sites (Baell and Walters 2014); however, antioxidants are not specific in their 
targets and therefore should not be classified as such. 
Regardless of the mechanism of action, much of the scientific literature fails to address 
the efficacy of green tea as a therapy. For example, the Unites States Department of Agriculture 
found that concentrations of EGCG in 100 g samples of different green teas varied over 100-fold, 
suggesting that its reliability as a consumable therapy is dubious at best (United States 
Department of Agriculture 2013). Scientists conducting research into the mechanisms of action 
utilized by EGCG often do not address the issue of EGCG’s concentration in the blood, which 
studies show is not highly realted with dose (Ahn et al. 2014; Anita et al. 2014; Audomkasok et 
al. 2014; Bashir et al. 2014; Delabre et al. 2015; Jeon et al. 2014; Lee et al. 2014a; Miranda-
Henriques et al. 2014; Nasri et al. 2013; Ohmori et al. 2014; Saleh et al. 2014; Table 2; Figure 1). 
Additionally, the concentrations of EGCG examined in laboratory studies using cell cultures and 
animal models, while meaningful within the scientific community, have little or no meaning to 
the general public and are generally regarded as far higher than physiologically achievable levels 
in humans (Lambert and Yang 2003). From a public health perspective, the conclusions drawn 
from some of these studies are difficult to assess in regard to their application to a broader 
audience. 
In this thesis, I will examine epidemiological, clinical, and laboratory studies 
investigating green tea’s effects on human health. I will also critically evaluate some of the 
proposed mechanisms of action of green tea required to produce the beneficial results to 
determine their feasibility within humans. Furthermore, I will assess EGCG’s potential 
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classification as a pan-assay interfering compound. The goal of this thesis is to determine 
whether green tea’s putative health benefits are scientifically supported — epidemiologically, 
clinically, and biochemically. 
Epidemiology of Green Tea Consumption 
Epidemiology is the study of the distribution and determinants (causes/risk factors) of morbidity 
(disease), injury, disability, and mortality within a population (Friis 2010). Epidemiologists use 
surveillance and descriptive studies to determine and track the distribution of health problems 
and analytical studies to investigate determinants (Friis 2010). Descriptive/surveillance 
epidemiology aims to characterize the amount and distribution of health conditions within a 
population, relying on the systematic collection, analysis, and distribution of information 
pertaining to the disease occurrence (Friis 2010). Analytic epidemiology focuses on studying the 
determinants of a disease within a population, examining the etiological (causal) factors linking 
exposures and health conditions (Friis 2010). Both of these epidemiological approaches allow a 
comprehensive examination of the incidence of a health condition within a community and 
provide information for intervention. 
Several epidemiological studies suggest that drinking green tea does have beneficial 
health effects. One of the largest epidemiological studies on the health benefits of green tea is the 
Ohsaki Study. From 1994 through 2005, the Ohsaki Study looked at the relationship between 
green tea and mortality for 40,530 healthy Japanese adults aged 40 to 79 from the Miyagi 
Prefecture in northeastern Japan (Kuriyama et al. 2006). A previous survey had reported that 
42% of people in the Miyagi Prefecture regularly drank five or more cups of green tea daily 
(Tsubono et al. 2001). The Ohsaki Study was designed as a prospective cohort, in which similar 
individuals who differ in a certain factor, in this case green tea consumption, are followed over 
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time to determine the effects of green tea consumption on a certain outcome, in this case 
mortality. The Ohsaki Study found that those who reported drinking five or more cups of green 
tea daily were significantly less likely to die during the period of observation than those who 
drank less than one cup per day (Kuriyama et al. 2006). 
One of the most prevalent claims relating to green tea’s health benefits is its ability to 
lower the risk for cardiovascular disease. Cardiovascular disease refers to conditions relating to 
the heart and the blood vessels and includes disorders such as arrhythmia, atherosclerosis 
(buildup of plaque in arteries), hypertension, congenital heart defects, stroke, and heart attack 
(Phinikaridou et al. 2013). As the leading cause of death in the United States, cardiovascular 
disease is responsible for one in every four deaths and costs $108.9 billion annually in lost labor 
and treatment (Heidenreich et al. 2011; Murphy et al. 2013). According to the Centers for 
Disease Control and Prevention (CDC), 49% of Americans have at least one of the three major 
risk factors for cardiovascular disease: high blood pressure, high LDL cholesterol, and smoking 
(Valderrama et al. 2011). There are many epidemiological studies that focus on the role of green 
tea in improving cardiovascular health. 
The Ohsaki Study noted a decrease in deaths due to cardiovascular disease in green tea 
drinkers. Women who drank five or more cups (1 cup = 100 mL) of green tea per day were 31% 
less likely to die from cardiovascular diseases during the observation period than those who 
drank less than one cup of green tea per day (Kuriyama et al. 2006). Another prospective cohort 
study, The Seven Countries Study, followed sixteen cohorts over twenty-five years starting in 
1960 and found that there was an inverse relationship between green tea intake and death due to 
coronary heart disease (Hertog et al. 1995). The Boston Area Study found that the risk of heart 
attack was reduced by 44% in those who drank one or more cups of green tea per day as 
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compared to non-green tea-drinking controls (Sesso et al. 1999). Finally, a study conducted in 
Taiwan found that consumption of between 120 mL and 599 mL of green tea daily reduced the 
development of hypertension by 46% and that drinking over 600 mL daily reduced the risk of 
hypertension by 65% (Yang et al. 2004). Each of these statistically significant results strengthens 
claims that green tea is capable of reducing the incidence of cardiovascular disease. 
As a strong risk factor for cardiovascular disease, diabetes has also been extensively 
examined epidemiologically in the search for new, natural therapies. Diabetes mellitus results 
from an inability to respond to and/or produce insulin, the hormone responsible for the uptake of 
glucose by cells (Philippe and Raccah 2009). Type 1 diabetes is an autoimmune disorder, 
whereas Type 2 is the progressive development of insulin resistance and secretion defects 
leading to varying degrees of decreased β-cell function in the pancreas (Cnop et al. 2005; Liese 
et al. 2013; U.K. Prospective 1995). Due to increased longevity and obesity, some researchers 
predict that the global incidence of Type 2 diabetes, currently at 7%, will increase to 15% by 
2030 (Boyle et al. 2010; Philippe and Raccah 2009; Wild et al. 2004). In the United States, 9.3% 
of the population suffers from diabetes and 95% of new cases in adults are Type 2 diabetes 
(Centers for Disease Control and Prevention 2014). 
Epidemiological studies on diabetes vary in their conclusions on the effectiveness of 
green tea as a potential therapy or preventative. One study of 17,000 Japanese men and women 
found that drinking six or more cups of green tea daily led to a 33% reduced risk of developing 
Type 2 diabetes (Iso et al. 2006). Another study found that drinking three cups of green tea daily 
for four weeks decreased blood pressure in 39.6% of Iranian Type 2 diabetes patients 
(Mozaffari-Khosravi et al. 2013). In contrast, the Singapore Chinese Health Study of over 36,000 
participants saw no association between the consumption of more than one cup of green tea daily 
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and a reduced risk for Type 2 diabetes (Odegaard et al. 2008). Therefore, it is not possible at 
present to say whether green tea is effective at reducing risk for Type 2 diabetes, and additional 
research will be necessary to elucidate the potential links between green tea and diabetes. 
Cancer is another area in which many epidemiological investigations regarding green 
tea’s health benefits have been conducted. Cancer results from the accumulation of mutations in 
genes that regulate cell proliferation (Samuels et al. 2011). These mutations lead to uncontrolled 
cell division without the normal checkpoints and regulation (Alberts et al. 2007). These 
mutations may be inherited, increasing one's risk of cancer, or occur spontaneously as the result 
of environmental exposure to tobacco or other chemical carcinogens, viruses, radiation, etc. 
(O’Connor et al. 2011). One nine-year study, conducted in Japan in the 1990s, found that 
females were statistically less likely to develop cancer of any type if they drank green tea 
regularly; however, the effect was only significant in those drinking on average ten or more cups 
of green tea daily (Imai et al. 1997). 
In 2013, there were 234,580 new cases of breast cancer reported in the United States 
along with 39,620 deaths (Rebecca and Jemal 2013). Many epidemiological studies suggest that 
green tea may have a beneficial effect for breast cancer patients (Li et al. 2014). A 2014 meta-
analysis (the application of statistics to data collected and pooled from multiple studies) from 
five case-control studies showed a statistically significant 19% reduction in breast cancer risk 
among green tea drinkers (Li et al. 2014). However, an earlier meta-analysis of eight studies 
concluded that there was not enough statistical support to suggest that green tea had any effect on 
reducing breast cancer incidence (Seely et al. 2005). While interesting, these studies are not 
conclusive and further research will need to be conducted into the relationship between green tea 
and breast cancer. 
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There is some compelling epidemiological evidence suggesting that green tea may 
provide therapeutic benefits in certain health conditions. While epidemiological studies are 
useful to observe effects in the context of daily life, it is impossible to control for all variables. 
For example, many of the epidemiological studies conducted on green tea take place in Asia. As 
a result, differences between these Asian populations and other populations around the world in 
regards to genetics, diet, microbiota, etc. are impossible to completely control for in 
epidemiological studies. These differences can confound efforts to analyze green tea's impact in 
other populations. The next logical step in evaluating green tea's efficacy as a therapy is to 
conduct clinical trials. 
Clinical Trials on Green Tea as a Therapy 
Clinical trials are prospective studies looking at the effect of an intervention — such as a drug, 
surgical procedure, diet, exercise regime, etc. — on human health (Friedman et al. 2010). An 
ideal clinical trial is one that has the following characteristics: 1) it is randomized — people are 
assigned to the intervention or control group in a random fashion; and 2) it is double-blind — 
neither the participants nor the investigators know to which group the participant was assigned 
(Friedman et al. 2010). In the United States, a clinical trial funded in part by the National 
Institutes of Health (NIH) and/or other government institutions is the gold standard in quality 
assurance. Currently, there are only six completed, NIH-funded clinical trials studying the 
efficacy of green tea as a preventative or therapeutic in various disorders — prostate cancer, 
chronic obstructive pulmonary disease, human papillomavirus (HPV), osteoporosis, chronic 
lymphocytic leukemia, and multiple sclerosis. Only three of these studies — examining HPV, 
osteoporosis, and chronic lymphoid leukemia — have published their results. 
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 Cervical cancer is the most common gynecological malignancy globally (Garcia et al. 
2014). Human papillomavirus (HPV) infection is implicated in greater than 99% of all cervical 
cancer cases (Bosch and de Sanjosé 2003). Previous studies suggested that treatment with green 
tea supplements might accelerate clearance of HPV infection (Ahn et al. 2003; Tatti et al. 2008). 
In one clinical trial, Garcia et al. (2014) investigated the effects of Polyphenon E, a concentrated 
green tea supplement, on prevention of cervical cancer in women with pre-cancerous growth as a 
result of HPV infection. Ninety-eight women were enrolled in the study, randomly sorted into 
the Polyphenon E group or the placebo group, and followed for four months. The study found no 
evidence that Polyphenon E treatment promoted the clearance of HPV infection (Garcia et al. 
2014). 
Osteoporosis is a degenerative bone disease characterized by lower bone density, which 
increases the risk for fractures and breaks (National Institutes of Health 2001). This condition 
causes an estimated 1.5 million fractures annually in the United States at a cost of $20 billion per 
year (Cooper et al. 2011; Cummings and Melton 2002). Postmenopausal women are four times 
more likely to develop osteoporosis than other populations because of a decrease in estrogen 
levels (Looker et al. 2010). A clinical trial conducted by Shen et al. (2012) enrolled one hundred 
and seventy-one postmenopausal women with osteopenia (lower than normal bone mineral 
density and therefore at risk for osteoporosis) to determine whether intervention with green tea 
supplements and an exercise regime with tai chi would improve their bone health. There were 
four study groups: 1) starch placebo control; 2) green tea supplement (500 mg/day); 3) placebo 
and tai chi for 60 minutes, three times per week; and 4) green tea supplement and tai chi (Shen et 
al. 2012). The researchers measured calcium metabolism through parathyroid hormone levels, 
muscle strength, and the serum levels of two bone turnover markers — bone-specific alkaline 
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phosphatase (BAP), which is indicates good bone density, and tartrate-resistant acid phosphatase 
(TRAP), which indicates poor bone density (Shen et al. 2012). Over the course of six months, 
they observed improved levels of parathyroid hormone and BAP, an improved BAP/TRAP ratio, 
and increased muscle strength due to the combination of green tea supplementation and tai chi 
(Shen et al. 2012). On the basis of this study, green tea supplementation alone improved BAP 
levels within one month, improved the BAP/TRAP ratio within three months, and increased 
muscle strength within six months. These results suggest that green tea (and tai chi) may be 
effective at maintaining bone mineral density in postmenopausal women (Shen et al. 2012). 
Chronic lymphocytic leukemia is the most common form of leukemia, with 15,000 new 
cases and 5,000 deaths annually in the United States (Nabhan and Rosen 2014). Many studies 
suggest that green tea has a therapeutic effect for leukemia and lymphoma patients (Frankenfeld 
et al. 2008; Kuo et al. 2009; Naganuma et al. 2009; Zhang et al. 2008). In this study, forty 
patients with asymptomatic, early stage chronic lymphocytic leukemia received Polyphenon E 
twice daily (Shanafelt et al. 2013). Following six months of treatment, the researchers saw 
significant declines in absolute lymphocyte count and lymphadenopathy, signs that the cancer 
was not progressing, in 70% of their patients (Shanafelt et al. 2013). These results suggest that 
green tea supplements may be effective at preventing the progression of chronic lymphocytic 
leukemia in early stage patients. 
While the trials discussed above suggest that green tea may play a role in maintaining 
bone mineral density and preventing the progression of leukemia, the mechanism by which green 
tea (or green tea supplements) accomplishes this remains unknown. Clinical trials are better at 
controlling variables than epidemiological studies, which often rely on self-reporting; however, 
clinical trials cannot completely eliminate confounding variables and/or compliance issues. 
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Clinical trials are currently the best way to measure drug safety and efficacy. The results of these 
studies, while modest, are somewhat encouraging for green tea's future as a clinical therapy. 
Biochemistry of Green Tea 
The United States Food and Drug Administration (FDA) does not require that the mechanism of 
action be understood for drugs before they enter into a clinical trial (Nature Medicine 2010). An 
editorial in Nature Medicine, one of the top international medical journals, argues that lack of 
knowledge about drug targets and mechanisms hinders the ability to prescribe drugs in a 
maximally beneficial manner (Nature Medicine 2010). Within green tea, there are fifteen active 
polyphenols known to interact with at least 200 different targets in humans, but the mechanisms 
are not well categorized (Figure 2). These targets can be further organized into seven disease 
groups, but without clearly defined mechanisms it is impossible to assess green tea's effects 
within these categories (Figure 2). For example, there are nine protein targets within the disease 
group diabetes, but how green tea polyphenols interact with these proteins and produce 
medically beneficial effects is not known (Figure 2). I present below two examples of proposed 
mechanisms that will elucidate the complexity and the ill-defined nature of this research. 
With respect to cardiovascular disease, researchers have investigated many different 
proposed mechanisms for EGCG’s role in disease control and prevention. Some scientists have 
highlighted the ability of green tea to reduce the risk of cardiovascular disease by acting as an 
anti-thrombotic, anti-oxidant, anti-hypertensive, anti-inflammatory, anti-proliferative, anti-
diabetic, and anti-mutagenic (Babu and Liu 2008; Basu and Lucas 2007). For example, in terms 
of anti-thrombotic action, there is a proposed interaction of EGCG with the enzyme plasminogen 
activator inhibitor-1 (PAI-1), a key molecule in the formation of a thrombus (Peng et al. 2008; 
Rijken and Lijnen 2009; Vaughan 2005). High levels of PAI-1 have been linked to an increased 
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risk for thrombus formation because they preclude the degradation of the extracellular matrix — 
the web of fibers and associated fluids between cells — by plasmin (Gils and Declerck 2004). 
Elevated PAI-1 has been demonstrated in a number of conditions including heart attack, 
coronary artery disease, deep vein thrombosis, and atherosclerosis (Declerck and Gils 2013). 
EGCG has been shown to hinder the action of PAI-1 in human cell cultures and this mechanism 
is thought to reduce the risk of atherosclerosis by inhibiting thrombus formation following the 
rupture of plaque built-up on the arterial wall (Cale et al. 2010; Cao et al. 2013). Thus, inhibition 
of PAI-1 by EGCG would reduce the risk of thrombus formation. 
As with cardiovascular disease, diabetes research has uncovered multiple potential 
mechanisms of action for how EGCG may act upon the endocrine system, metabolism, redox 
states, and various cell types to reduce the incidence and impact of Type 2 diabetes and obesity 
(Kao et al. 2006). For example, one research group used a diabetic mouse model to examine 
EGCG’s effect on glucose tolerance (Ortsäter et al. 2012). After ten weeks, the fasting blood 
glucose levels for the control group rose to 14.7 mM and the EGCG supplemented mice saw a 
concentration of 9.3 mM, a statistically significant drop (Ortsäter et al. 2012). However, mice 
treated with a current diabetic drug — rosiglitazone — had a fasting blood glucose level of only 
4.0 mM after ten weeks (Ortsäter et al. 2012). EGCG is less effective than rosiglitazone, but still 
produced a statistically significant drop in blood glucose levels in mice, and EGCG may prove to 
be a less toxic and cheaper option. 
Developing a comprehensive mechanistic characterization of EGCG and the other 
compounds in green tea is crucial in determining whether or not green tea will prove an effective 
therapy for any health conditions. However, the lack of consensus in the literature makes it 
challenging to identify the truly promising actions. In addition, the concentrations of EGCG 
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required to achieve even minimally beneficial effects for both atherosclerosis and diabetes are 
large and not reasonably achieved through the consumption green tea alone — the most effective 
dose of EGCG in the atherosclerosis study described above was 50 µM and in a cell-culture 
diabetes study was 10 µM (Table 2, Figure 1; Cao et al. 2013; Kim et al. 2013). In humans, the 
largest dose of EGCG for which data are available — the equivalent of at least 180 cups of green 
tea, assuming a generous 10 mg of EGCG per cup — only produced a maximum plasma 
concentration of just over 6 µM (Table 2, Figure 1). Also, as discussed earlier, the amount of 
EGCG in green tea can vary dramatically, which raises a number of questions regarding effective 
dosing (United States Department of Agriculture 2013). 
The proposed mechanisms discussed above do not begin to scratch the surface of the 
potential mechanisms and targets in the literature of EGCG and green tea within the vast array of 
human disorders in which it is implicated (Figure 2). Given the numerous potential mechanisms 
involved in the cardiovascular system and diabetes, EGCG and other components in green tea 
seem to appear everywhere researchers look — suggesting that EGCG may qualify for 
classification as a PAIN. 
The Bioavailability of Green Tea 
Bioavailability is a measure of the amount of a drug that enters into circulation — the higher a 
drug’s bioavailability, the greater the drug’s effectiveness (Chow and Liu 2009). Bioavailability 
falls under the umbrella field of pharmacokinetics — the study of the fate of drugs upon 
administration, for example how much of the drug ends up in circulation or is lost as waste 
(Shargel et al. 2012). There have been numerous studies on the bioavailability of polyphenols 
such as EGCG (Table 2, Figure 1), and they do no appear to be readily bioavailable in the body 
for reasons that are not completely understood (Manach et al. 2004). An important measure of 
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bioavailability is the Cmax of a drug, which is the maximum concentration that a drug reaches in 
blood plasma (Urso et al. 2002). Pharmacokinetic studies conducted with green tea show a large 
variability in the Cmax of EGCG, ranging from 0.02-6.35 µM in blood plasma (Table 2, Figure 1). 
The correlation coefficient, r, is a measure of the strength of a relationship between two variables 
— the closer the r value is to 1, the stronger the relationship; whereas, another measure of the 
relationship between variables, the coefficient of determination, r2, looks at the predictability of 
changes in one variable producing consistent changes in another variable— an r2 value closer to 
1, means that changes in the independent variable (in our case dose of EGCG) are a better 
predictor of changes in the dependent variable (in our case Cmax) (Gerstman 2014). On the basis 
of a linear regression analysis, there is a positive relationship between dose of EGCG and plasma 
concentration (F1,24 = 28.18; p-value ≤ 0.001; r = 0.73; r
2 = 0.54; Figure 1), but the removal of 
three clear outliers noticeably reduces this relationship (F1,20 = 11.66; p = 0.003; r = 0.61; r
2 = 
0.37). This variability of EGCG’s bioavailability is a challenge when attempting to provide 
reliable dosing. 
The less than ideal relationship between dose and plasma concentration may be related to 
the variable amounts of EGCG among similar green tea doses. The USDA Database for the 
Flavonoid Content of Selected Foods found that brewed green teas have anywhere between 2.3 
mg and 203 mg EGCG per 100 g serving (United States Department of Agriculture 2013). This 
variability in the amount of EGCG further suggests that green tea, as a beverage, may prove 
ineffective as a medicinal therapy. Even with the generous assumption of 10 mg EGCG per cup 
of tea, an unrealistic amount of green tea would be required to achieve the necessary 
physiologically levels to see any benefit, as noted in the previous section. It appears impossible 
for any individual to drink enough green tea to significantly improve their health outcomes. 
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Green Tea and Liver Damage 
Given the studies examined thus far, it does not seem possible for the average human to attain 
the necessary concentrations of EGCG to experience beneficial health outcomes from drinking 
green tea alone (Table 2, Figure 1). Thus, it is reasonable to assume that if EGCG is to be used as 
a drug it will most likely be in the form of a concentrated supplement containing high doses of 
EGCG. However, there are numerous studies in which researchers have found that high doses of 
EGCG can cause liver damage in both humans and rodents (Chen et al. 2010; Emoto et al. 2014; 
Galati et al. 2006; Gallo et al. 2013; Goodin 2006; Lambert et al. 2010; Mazzanti et al. 2009; 
Molinari et al. 2006; Patel et al. 2013; Salminen et al. 2012; Shanafelt et al. 2013). Some of these 
studies describe only a single case and/or potential interference by other medications (Emoto et 
al. 2014; Mazzanti et al. 2009), while others involved high concentrations of EGCG and long-
periods of exposure (Emoto et al. 2014). All drugs have toxic concentrations; however, at 
present, the concentration of and length of exposure to EGCG that would lead to liver damage is 
unknown (Emoto et al. 2014). The potential for harmful side effects following prolonged 
exposure and/or high doses — greater than 400 mg EGCG per dose, or about 20 cups of green 
tea, in humans typically for over a month — raise concerns over whether EGCG could ever be 
used for therapeutic purposes (Emoto et al. 2014). 
Conclusions: Green Tea, Panacea or PAIN? 
Is green tea a panacea or a PAIN? Scientists really do not know. The research into green tea’s 
role as a drug is burgeoning, conflicting, and inconclusive. There is strong epidemiological 
evidence from multiple large studies suggesting that drinking green tea improves health 
outcomes of certain populations (Hertog et al. 1995; Iso et al. 2006; Kris-Etherton and Keen 
2002; Kuriyama et al. 2006; Mozaffari-Khosravi et al 2013; Odegaard et al. 2008; Sesso et al. 
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1999; Yang et al 2004). However, clinical trials funded by the National Institutes of Health are 
very few in number and demonstrate only modest results (Garcia et al. 2014; Shanafelt et al. 
2013; Shen et al. 2012). The bioavailability of EGCG and other green tea polyphenols is poorly 
understood (Manach et al. 2004), and the wide range of EGCG present in green tea raises 
concerns that the dose is not consistent between cups (United States Department of Agriculture 
2013). Laboratory studies often involve large doses of concentrated EGCG that are well beyond 
the amounts that could be consumed by ingestion and there are some warning signs that large 
doses of EGCG may lead to liver damage (Emoto et al. 2014; Lambert and Yang 2003). Finally, 
there is concern about the specificity of EGCG and other polyphenols found in green tea, as 
many of them may turn out to be pan-assay interfering compounds (Baell 2010). 
The health claims regarding green tea made to the general public are clearly over-stated. 
While epidemiological studies look promising, clinical and laboratory trials to date are not 
compelling, requiring large doses and producing poorly defined benefits. Enjoying a few cups of 
green tea daily will not harm you, but it probably will not save you from cardiovascular disease, 
cancer, diabetes, or any other disease. In the absence of convincing mechanisms and consistent 
dosing, it is difficult to see green tea, or any of its components, rising to pharmaceutical status. 
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Table 1. Recent research studies involving green tea and health. 
Study 
Organism/Cells 
Examined 
Disease/Condition 
Discusses 
Mechanism 
Discusses 
Bioavailability 
Discusses 
Dose* 
Fatemi et al. 
2014 
Rats Burns No N/A, topical No 
Neturi et al. 
2014 
Humans 
Streptococcus 
mutans count in 
mouth 
No N/A, oral rinse No 
Lee et al. 
2014b 
Mice Wrinkles No N/A, topical No 
Ohmori et al. 
2014 
Humans 
Coronary Artery 
Disease 
No No 
7 cups per 
day 
Liu et al. 2015 
Human Liver 
Cells in Culture 
Cholesterol 
Metabolism 
Yes No No 
Anita et al. 
2014 
Cariogenic 
Bacteria in 
Culture 
Antibiotic 
Properties 
No N/A No 
Jiang et al. 
2014 
Human 
Osteosarcoma 
Cells in Culture 
Osteosarcoma Yes No No 
Delabre et al. 
2015 
Humans Influenza No No 
Two cups 
per week 
minimum 
Audomkasok 
et al. 2014 
Mice 
Malaria 
(Plasmodium 
berghei) 
No No No 
Ahn et al. 
2014 
Rats 
Cisplatin-Induced 
Nephrotoxicity 
No No No 
Huang et al. 
2015 
Rabbits 
Autologous 
Chondrocyte 
Implantation 
Yes No No 
Gu et al. 2014 Rats 
Chronic 
Unpredictable Mild 
Stress-Induced 
Cognitive 
Impairment 
Yes No No 
Liu et al. 2014 
Human Aortic 
Smooth Cells in 
Culture 
Atherosclerosis Yes No No 
Khan et al. 
2014 
Rats 
Doxorubicin-
Induced 
Cardiotoxicity 
Yes No No 
Nasri et al. 
2013 
Rats 
Contrast Media-
Induced Acute 
Renal Damage 
No No No 
Suthar et al. 
2014 
Human 
Erythrocytes in 
Culture 
Bisphenol A-
Induced Oxidative 
Stress 
Yes No No 
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Table 1 (continued). Recent research studies involving green tea and health. 
Study 
Organism of 
Study 
Disease/Condition 
Discusses 
Mechanism 
Discusses 
Bioavailability 
Discusses 
Dose* 
Jeon et al. 
2014 
Bacteria from 
Human Skin 
Wounds in 
Culture 
Bacterial 
(Pseudomonas 
aeruginosa and 
Escherichia coli) 
Infection of Skin 
Wounds 
No No No 
Bashir et al. 
2014 
Bacterial 
Cultures 
Antibacterial No No No 
Miranda-
Henriques et 
al. 2014 
Rats 
Nonalcoholic 
Steatohepatitis 
No No No 
Lodhi et al. 
2014 
Rats 
Chronic Ethanol-
Induced 
Hepatotoxicity 
Yes No No 
Chakraborty et 
al. 2014 Rats 
Cyclophosphamide-
Induced Myocardial 
Damage 
Yes No No 
Zhao et al. 
2014 
Rat Embryo 
Spinal Cord 
Neurons in 
Culture 
Spinal Cord 
Neuronal Oxidative 
Damage 
Yes No No 
Shin et al. 
2014 
Rats 
Postsurgical 
Adhesions 
Yes No No 
Saleh et al. 
2014 
Human Blood 
Cells from 
Breast Cancer 
Patients in 
Culture 
Peripheral Blood 
Mononuclear Cells 
Proliferation in 
Breast Cancer 
No No No 
Lee et al. 
2014a 
Human Retinal 
Pigmented 
Epithelial Cells 
in Culture 
Ocular Angiogenic 
Disease 
Yes No No 
 
* In public health relevant units such as ounces, cups, or grams of tea leaves. 
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Table 2. The varied bioavailability of EGCG. 
Amount of EGCG Cmax in Plasma Study/Review 
37 mg 0.020 µM Warden et al. 2001* 
50 mg 0.260 µM Ullmann et al. 2003* 
63 mg 0.330 µM Unno et al. 2005 
67 mg 0.170 µM Lee et al. 2002 
75 mg 0.080 µM Del Rio et al. 2010 
100 mg 0.410 µM Ullmann et al. 2003* 
105 mg 0.055 µM Stalmach et al. 2009 
110 mg 0.260 µM Yang et al. 1998 
112 mg 0.125 µM Williamson et al. 2011 
134 mg 0.080 µM Renouf et al. 2010 
200 mg 0.160 µM Chow et al. 2001* 
200 mg 0.710 µM Ullmann et al. 2004* 
200 mg 0.680 µM Ullmann et al. 2003* 
200 mg 0.150 µM Meng et al. 2002* 
214 mg 0.080 µM Henning et al. 2004 
219 mg 0.710 µM Yang et al. 1998 
329 mg 0.700 µM Yang et al. 1998 
400 mg 0.240 µM Chow et al. 2001* 
400 mg 1.100 µM Ullmann et al. 2004* 
400 mg 1.240 µM Ullmann et al. 2003* 
600 mg 0.370 µM Chow et al. 2001* 
800 mg 0.960 µM Chow et al. 2001* 
800 mg 4.950 µM Ullmann et al. 2004* 
800 mg 2.100 µM Ullmann et al. 2003* 
1200 mg 0.113 µM Lee et al. 1995 
1600 mg 6.350 µM Ullmann et al. 2003* 
 
*Found in: Feng 2006 
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Figure Legends 
Figure 1. The relationship between Cmax and EGCG dose in humans, based on data obtained 
from the twenty-six studies listed in Table 2 (r = 0.73, r2 = 0.54 for all studies; r = 0.61, r2 = 0.37 
following removal of outliers, indicated by black diamonds). 
 
Figure 2. The main targets for green tea polyphenols in humans. Fifteen green tea polyphenols 
(diamonds) are linked to two-hundred protein targets (circles) via lines (grey), which are divided 
into seven disease categories (from Zhang et al. 2014). 
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Figure 1 
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Figure 2 
 
 
 
